{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:10Z","timestamp":1781643430710,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The overall incidence of pituitary apoplexy among patients with pituitary adenoma ranges from 0.6% to 7.0%, although many cases likely go undiagnosed. Several precipitating factors have been identified, and a small number of case reports have suggested an association between immune checkpoint inhibitors and pituitary apoplexy, particularly in patients with preexisting adenoma. Moreover, the safety of immune checkpoint inhibitor rechallenge remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The patient was a 71-year-old woman with a recurrence of metastatic primary rectal melanoma. A pituitary tumor had been identified before initiation of systemic therapy. Following the second cycle of nivolumab plus ipilimumab, the patient developed headache, nausea, and vomiting, followed by decreased serum thyroid-stimulating hormone, adrenocorticotrophic hormone, and luteinizing hormone levels. These findings were consistent with evolving hypopituitarism. Contrast-enhanced magnetic resonance images revealed hemorrhage in the pituitary adenoma, suggesting pituitary apoplexy. Eight months after discontinuation of nivolumab plus ipilimumab, disease progression was noted, and nivolumab monotherapy was resumed. There was no recurrence of pituitary apoplexy during six cycles of nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights that pituitary apoplexy can occur temporally after nivolumab plus ipilimumab treatment in patients with preexisting pituitary adenoma. Importantly, nivolumab monotherapy rechallenge under close monitoring may be feasible without recurrence of pituitary apoplexy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00564-4","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:14:11Z","timestamp":1773940451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review"],"prefix":"10.1186","volume":"12","author":[{"given":"Chiaki","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1590\/2359-3997000000047","volume":"59","author":"A Glezer","year":"2015","unstructured":"Glezer A, Bronstein MD. Pituitary apoplexy: pathophysiology, diagnosis and management. Arch Endocrinol Metab. 2015;59:259\u201364.","journal-title":"Arch Endocrinol Metab"},{"key":"564_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jocn.2014.11.023","volume":"22","author":"PC Johnston","year":"2015","unstructured":"Johnston PC, Hamrahian AH, Weil RJ, Kennedy L. Pituitary tumor apoplexy. J Clin Neurosci. 2015;22:939\u201344.","journal-title":"J Clin Neurosci"},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1210\/er.2015-1042","volume":"36","author":"C Briet","year":"2015","unstructured":"Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary Apoplexy. Endocr Rev. 2015;36:622\u201345.","journal-title":"Endocr Rev"},{"key":"564_CR4","first-page":"372","volume":"41","author":"F Proust","year":"1995","unstructured":"Proust F, Hannequin D, Bellow F, Langlois O, Tadi\u00e9 M, Creissard P, et al. [Stress-induced pituitary apoplexy in 2 phases]. Neurochirurgie. 1995;41:372\u20136.","journal-title":"Neurochirurgie"},{"key":"564_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2265.2010.03913.x","volume":"74","author":"S Rajasekaran","year":"2011","unstructured":"Rajasekaran S, Vanderpump M, Baldeweg S, Drake W, Reddy N, Lanyon M, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf). 2011;74:9\u201320.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"564_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11102-014-0616-3","volume":"19","author":"F Doglietto","year":"2016","unstructured":"Doglietto F, Costi E, Villaret AB, Mardighian D, Fontanella MM, Giustina A. New oral anticoagulants and pituitary apoplexy. Pituitary. 2016;19:232\u20134.","journal-title":"Pituitary"},{"key":"564_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13256-018-1782-0","volume":"12","author":"L Carril-Ajuria","year":"2018","unstructured":"Carril-Ajuria L, Jimenez-Aguilar E, Gomez-Martin C, Diaz-Pedroche C. An unsuspected complication with immune checkpoint blockade: a case report. J Med Case Rep. 2018;12:246.","journal-title":"J Med Case Rep"},{"key":"564_CR8","doi-asserted-by":"crossref","unstructured":"Lopes SAS-CL, Momjian S, Ben Aissa A, Brocco E, Becquart O, Egervari K, Merkler D, Jornayvaz F, Leboulleux S, Mavromati M. Pituitary macroadenoma apoplexy following treatment with pembrolizumab. J Endocr Soc. 2023;90:EP705.","DOI":"10.1530\/endoabs.90.EP705"},{"issue":"Suppl 1","key":"564_CR9","doi-asserted-by":"publisher","first-page":"bvad1141067","DOI":"10.1210\/jendso\/bvad114.1067","volume":"7","author":"A Uddin","year":"2023","unstructured":"Uddin A, Gardner MJ, Akofu A, Sheung N, Dejhansathit S, Akabogu N, et al. SAT437 Immunotherapy Induced Pituitary Apoplexy. J Endocr Soc. 2023;7(Suppl 1):bvad1141067.","journal-title":"J Endocr Soc"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"108376","DOI":"10.1016\/j.lungcan.2025.108376","volume":"200","author":"H Hayhurst","year":"2025","unstructured":"Hayhurst H, Oluwashegon D, Greystoke A. 267 Pituitary apoplexy occurring in a patient with a known pituitary macroadenoma following treatment with immunotherapy. Lung Cancer. 2025;200:108376.","journal-title":"Lung Cancer"},{"key":"564_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","journal-title":"Lancet"},{"key":"564_CR12","doi-asserted-by":"publisher","first-page":"175883592092202","DOI":"10.1177\/1758835920922028","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Kan H, Zhao L, Sun Z, Bai C. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. Ther Adv Med Oncol. 2020;12:1758835920922028.","journal-title":"Ther Adv Med Oncol"},{"key":"564_CR13","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.2147\/CMAR.S224791","volume":"12","author":"M Tsoli","year":"2020","unstructured":"Tsoli M, Kaltsas G, Angelousi A, Alexandraki K, Randeva H, Kassi E. Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies. Cancer Manag Res. 2020;12:9551\u201361.","journal-title":"Cancer Manag Res"},{"key":"564_CR14","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230ra45.","journal-title":"Sci Transl Med"},{"key":"564_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","volume":"14","author":"G Di Dalmazi","year":"2019","unstructured":"Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019;14:381\u201398.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"bvac113","DOI":"10.1210\/jendso\/bvac113","volume":"6","author":"D Donegan","year":"2022","unstructured":"Donegan D, Erickson D. Revisiting Pituitary Apoplexy. J Endocr Soc. 2022;6:bvac113.","journal-title":"J Endocr Soc"},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/clinem\/dgab672","volume":"107","author":"F Langlois","year":"2022","unstructured":"Langlois F, Varlamov EV, Fleseriu M. Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease. J Clin Endocrinol Metab. 2022;107:10\u201328.","journal-title":"J Clin Endocrinol Metab"},{"key":"564_CR18","first-page":"1683","volume":"41","author":"R Kurokawa","year":"2020","unstructured":"Kurokawa R, Ota Y, Gonoi W, Hagiwara A, Kurokawa M, Mori H, et al. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis. AJNR Am J Neuroradiol. 2020;41:1683\u20139.","journal-title":"AJNR Am J Neuroradiol"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"21666","DOI":"10.1002\/cam4.6724","volume":"12","author":"Y Tasaki","year":"2023","unstructured":"Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, et al. Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. Cancer Med. 2023;12:21666\u201379.","journal-title":"Cancer Med"},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"1483956","DOI":"10.3389\/fimmu.2024.1483956","volume":"15","author":"Y Tasaki","year":"2024","unstructured":"Tasaki Y, Hamamoto S, Yamashita S, Furukawa J, Fujita K, Tomida R, et al. Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study. Front Immunol. 2024;15:1483956.","journal-title":"Front Immunol"},{"key":"564_CR21","doi-asserted-by":"publisher","first-page":"1112409","DOI":"10.3389\/fimmu.2023.1112409","volume":"14","author":"WT Hu","year":"2023","unstructured":"Hu WT, Zhang Q, Zhang Z, He X, Zhou M, Guo Y, et al. Eosinophil and IFN-gamma associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. Front Immunol. 2023;14:1112409.","journal-title":"Front Immunol"},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17:389\u201399.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00564-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:30:47Z","timestamp":1781641847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00564-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00564-4","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report, in accordance with the journal\u2019s patient consent policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IO: IO reports research funding from Taiho Pharmaceutical Co., Ltd. and Astellas Pharma Inc.; and lecture honoraria from AstraZeneca K.K., Novartis Pharma K.K., Nihon Servier Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. All items are outside the submitted work; the organizations had no involvement in the submitted study.YT: Within the past 36 months, YT has received speaker honoraria from AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Pfizer Japan Inc., Myriad Genetics Japan K.K., Eli Lilly Japan K.K., AbbVie G.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and Novartis Pharma K.K.; served as an internal IRB committee member for Oncolys BioPharma Inc.; and received scholarship donations from Chugai Pharmaceutical Co., Ltd. and Boehringer Ingelheim Japan, Inc. All items are outside the submitted work; the organizations had no involvement in the submitted study.All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}